
VistaGen Therapeutics Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 36 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in VistaGen Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VTGN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Active traders

VistaGen Therapeutics stock price (NASDAQ: VTGN)
Use our graph to track the performance of VTGN stocks over time.VistaGen Therapeutics shares at a glance
Latest market close | $0.88 |
---|---|
52-week range | $0.86 - $3.46 |
50-day moving average | $1.13 |
200-day moving average | $1.68 |
Wall St. target price | $7.33 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.34 |
Buy VistaGen Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy VistaGen Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
VistaGen Therapeutics price performance over time
Historical closes compared with the close of $0.875 from 2022-07-05
1 week (2022-06-30) | -0.57% |
---|---|
1 month (2022-06-03) | N/A |
3 months (2022-04-07) | -31.10% |
6 months (2022-01-04) | -55.58% |
1 year (2021-07-07) | -72.83% |
---|---|
2 years (2020-07-07) | 65.50% |
3 years (2019-07-05) | 24.29% |
5 years (2017-07-06) | 1.8 |
VistaGen Therapeutics financials
Revenue TTM | $1.1 million |
---|---|
Gross profit TTM | $1.1 million |
Return on assets TTM | -32.65% |
Return on equity TTM | -58.62% |
Profit margin | 0% |
Book value | $0.31 |
Market capitalisation | $181.8 million |
TTM: trailing 12 months
VistaGen Therapeutics share dividends
We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.
Have VistaGen Therapeutics's shares ever split?
VistaGen Therapeutics's shares were split on a 1:20 basis on 13 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.
VistaGen Therapeutics share price volatility
Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.86 up to $3.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.9505. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).
VistaGen Therapeutics overview
VistaGen Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd. ; license agreement with Pherin Pharmaceuticals, Inc.
VistaGen Therapeutics in the news
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
Frequently asked questions
What percentage of VistaGen Therapeutics is owned by insiders or institutions?Currently 0.349% of VistaGen Therapeutics shares are held by insiders and 69.285% by institutions. How many people work for VistaGen Therapeutics?
Latest data suggests 36 work at VistaGen Therapeutics. When does the fiscal year end for VistaGen Therapeutics?
VistaGen Therapeutics's fiscal year ends in March. Where is VistaGen Therapeutics based?
VistaGen Therapeutics's address is: 343 Allerton Avenue, South San Francisco, CA, United States, 94080 What is VistaGen Therapeutics's ISIN number?
VistaGen Therapeutics's international securities identification number is: US92840H2022 What is VistaGen Therapeutics's CUSIP number?
VistaGen Therapeutics's Committee on Uniform Securities Identification Procedures number is: 92840H103
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert